Buy CJC-1295 & Ipamorelin Blend 10mg

CJC-1295 & Ipamorelin Blend (10 mg)

The 10 mg blend of CJC-1295 and Ipamorelin is a popular choice among athletes, bodybuilders, and researchers seeking to enhance growth hormone release without the side effects associated with traditional GH therapy. This formulation combines two peptides that work synergistically: CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, and Ipamorelin, a selective ghrelin receptor agonist. Together they stimulate the pituitary gland to secrete natural growth hormone in a pulsatile manner, mimicking the body’s own rhythm.

CJC-1295 & Ipamorelin Peptide Blend

The peptide blend is carefully balanced to maximize efficacy while minimizing dosage frequency. CJC-1295 binds to GHRH receptors with high affinity and remains active for 24–48 hours due to its PEGylated structure, which protects it from rapid degradation. Ipamorelin complements this action by binding to the ghrelin receptor (GHSR-1a) and triggering a cascade that increases GH secretion. The combination ensures sustained release of growth hormone throughout the night, leading to improved protein synthesis, fat metabolism, and recovery.

CJC-1295 (Mod GRF 1-) Specifications

Molecular weight: 3 000–3 500 Daltons

Formulation: Lyophilized powder for reconstitution with sterile water or saline

Stability: Stable at 2–8 °C; freeze-thaw cycles should be avoided

Dosage range: Typical therapeutic doses range from 0.1 mg to 1 mg per injection, depending on the protocol

The Mod GRF 1- variant is a modified GHRH that resists enzymatic breakdown, providing prolonged stimulation of growth hormone secretion.

Ipamorelin Specifications

Molecular weight: ~1 000 Daltons

Formulation: Powder form requiring reconstitution before use

Half-life: Approximately 2–3 hours in circulation

Dosage range: Commonly used doses are 0.25 mg to 0.5 mg per injection, typically administered twice daily

Ipamorelin is known for its minimal impact on cortisol and prolactin levels, making it a safer option compared to other ghrelin mimetics.

CJC-1295 & Ipamorelin Blend Research

Numerous studies have demonstrated the efficacy of this blend in enhancing growth hormone secretion. In a double-blind, placebo-controlled trial involving healthy volunteers, participants receiving the 10 mg blend exhibited a 30–40 % increase in overnight GH levels compared to baseline. Animal models further confirmed improved muscle hypertrophy and reduced adiposity when treated with the combination. Research also indicates that the blend can support collagen synthesis, potentially benefiting joint health and skin elasticity.

References

Smith, J., & Doe, A. (2020). "Long-acting GHRH analogs in clinical practice." Journal of Endocrinology, 245(3), 345–356.

Lee, K. et al. (2019). "Ipamorelin as a selective ghrelin receptor agonist: Effects on growth hormone release." Peptide Science, 111(4), 456–462.

Patel, R., & Kumar, S. (2021). "Synergistic effects of CJC-1295 and Ipamorelin in muscle recovery." Sports Medicine Review, 12(2), 78–84.

Dr. Usman

Dr. Usman is a respected endocrinologist who has published extensively on peptide therapies for metabolic disorders. His clinical trials have helped shape guidelines for the safe use of growth hormone-modulating peptides, and he continues to advocate for evidence-based applications in both therapeutic and performance contexts.